IR-Med Inc. (IRME)
| Market Cap | 69.98M |
| Revenue (ttm) | 34,000 |
| Net Income (ttm) | -4.22M |
| Shares Out | 69.98M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1.000 |
| Previous Close | 1.000 |
| Day's Range | n/a |
| 52-Week Range | 0.585 - 1.650 |
| Beta | 1.56 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About IRME
IR-Med Inc., a medical device company, engages in the development of non-invasive devices for various medical indications. The company's development products pipeline consists of PressureSafe, a handheld optical monitoring device that supports early detection of pressure injuries to the skin and underlying tissue primarily caused by prolonged pressure associated with bed confinement; DiaSafe, a handheld optical monitoring device, which supports early detection of diabetic foot ulcers in lower limb skin and underlying tissue caused by prolonged ... [Read more]
News
IR-MED's PressureSafe™ Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel's Largest HMO
Poster presentation available here: LINK
IR-MED's PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries
Rosh Pina, Israel, April 05, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis tec...
IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries
Rosh Pina, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis tech...
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16
Rosh Pina, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis tech...
IR-MED Awarded Most Innovative Non-Invasive Diagnostics Technology Developer 2023 by Corporate Vision Magazine
Rosh Pina, Israel, Dec. 21, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis techn...
IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue
The Granted patent covers IR-MED's PressureSafe ™ decision support device for the early detection of pressure injuries addressing a healthcare burden that amounts to $26.8 billion in the U.S. annually...
IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer
Mr. Di-Cori's vast healthcare experience includes President of LifeWatch Technologies, a developer of technologies that help physicians detect symptoms before they become major health problems
IR-MED to Conduct Usability Study with Methodist Healthcare of San Antonio for its PressureSafe Device Which is Slated for U.S. Launch in H1 2024
Rosh Pina, Israel, Sept. 26, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis tech...
IR-MED Appoints Richard Serbin, Esq. to its Advisory Board
Rosh Pina, Israel, Sept. 13, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), a developer of a noninvasive AI-driven spectrographic analysis technology platform to addre...
IR-MED Chairman & Interim CEO Issues Letter to Shareholders
Rosh Pina, Israel, Aug. 21, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven infrared spectrographic analysis technology platform to...
IR-MED's AI-Powered Infra-Red Spectrographic Decision Support System PressureSafe Device Demonstrates High Efficacy in Detecting Pressure Injuries with 96% Accuracy: Potential to Set a New Standard of Care
Rosh Pina, Israel, July 17, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven Infra-Red spectrographic analysis technology platform t...
IR-Med Appoints Dr. Lynn Eschenbacher to its Advisory Board as Company Advances Toward Launch of its PressureSafe Wound Care Device
Rosh Pina, Israel, June 07, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven spectrographic analysis technology platform to address ...
IR-Med's PressureSafe Noninvasive Wound Care Device to be Demonstrated at Northwell Health's 10th Annual Shining the Light on Wound Care Symposium
Rosh Pina, Israel, May 19, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven spectrographic analysis technology platform to address s...
IR-Med to present at National Pressure Injury Advisory Panel 2023
The company's PressureSafe device is being designed to reduce healthcare disparity in pressure injury detection and treatment
IR-MED SIGNS AGREEMENT TO EXPAND ITS PRESSURESAFE DEVICE USABILITY STUDY
The study will expand to Rabin Medical Center (RMC), in parallel to Beit-Rivka, turning the study to a double c enter usability study.
IR-Med Gains Momentum in 2022
Biotech company makes significant progress on its PressureSafe device, teeing up entry into U.S. market in 2023 ROSH PINNA, Israel , Feb. 8, 2023 /PRNewswire/ -- "IR-MED" or the "Company" (OTCQB:IRME)...
IR-Med Announces Dr. David Dalton as Advisory Board member
Dr. Dalton brings decades of experience as a hall of fame CEO, entrepreneur, pharmaceutical executive and founder of over 40 companies
IR-Med Signs Agreement for the Commercial Design of the PressureSafe Device
Rosh Pinna, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- (“IR-MED or the “Company”) (OTCQB: IRME), an innovative medical device company that is developing non-invasive, real-time detection devices utiliz...
IR-Med files Provisional Patent Application Covering Additional Features of its PressureSafe Device for Early Detection of Pressure Injuries
Rosh Pinna, Israel, Aug. 12, 2022 (GLOBE NEWSWIRE) -- (“IR-MED or the “Company”) (OTCQB: IRME), an innovative medical device company, developing non-invasive, real-time detection devices that utilize ...
IR-Med To Initiate Useability Study of its PressureSafe Device
Rosh Pinna, Israel, June 23, 2022 (GLOBE NEWSWIRE) -- (“IR-MED or the “Company”) (OTCQB: IRME), an innovative development stage medical device company that utilizes Infra-Red light spectroscopy (IR) c...
IR-MED Names Moshe Gerber as New CEO
ROSH PINNA, Israel--(BUSINESS WIRE)--IR-Med (“IR-MED or the “Company”) (OTCQB:IRME), an innovative development-stage medical device company utilizing Infra-Red light spectroscopy (IR) and Artificial I...
IR-Med Announces $3.2 Million Private Placement
ROSH PINNA, Israel--(BUSINESS WIRE)--IR-Med (“IR-MED or the “Company”) (OTCQB:IRME), an innovative development stage medical device company that utilizes Infra-Red light spectroscopy (IR) combined wit...
Following Its Recent Annual Updates: IR-Med Announces OTCQB Up-listing: “A Significant Achievement for the Company”
ROSH PINNA, Israel--(BUSINESS WIRE)---- $IRME #AI--Following its recent annual updates: IR-Med announces OTCQB up-listing: “A significant achievement for the Company”.
IR-Med to Announce 2022 Goals: Anticipated POC Results, File for FDA Clearance and up Listing to the OTCQB
TEL AVIV, Israel--(BUSINESS WIRE)---- $IRME--IR-Med (OTC: IRME) (“Company” or “the Company”) is proud to announce a series of corporate updates to its investors regarding the medical, financial, and c...
IRME Letter to Shareholders
New York, N.Y., Jan. 11, 2022 (GLOBE NEWSWIRE) -- IR-Med, Inc. (OTCPINK: IRME).